Thiol exchange: An in vitro assay that predicts the efficacy of novel homocysteine lowering therapies

Journal of Pharmaceutical Sciences

Volumn 95, Issue 8, 2006, Pages 1742-1750

  Urquhart, Bradley L ^a,b   House, Andrew A ^a,b   Cutler, Murray J ^a,b   Spence, J David ^a,c   Freeman, David J ^a,b,d  

^a WESTERN UNIVERSITY   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Atherosclerosis; Clinical pharmacokinetics; Dose response; Homocysteine; HPLC; Protein binding; Renal clearance; Thiol exchange

Indexed keywords

ACETYLCYSTEINE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; IFOSFAMIDE; MESNA; PENICILLAMINE; SUCCIMER; TAURINE; THIOL DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; IN VITRO STUDY; NORMAL HUMAN; PROTEIN PROTEIN INTERACTION;

EID: 33747190369     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20680     Document Type: Review

References (36)

1. Finkelstein JD. 1998. The metabolism of homocysteine: Pathways and regulation. Eur J Pediatr 157:S40-S44.
2. Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR, Jacobsen DW, Brattstrom L, Wilcken B, Wilcken DE, Blom HJ, Stabler SP, Allen RH, Selhub J, Rosenberg IH. 2000. Homocysteine and its disulfide derivatives: A suggested consensus terminology. Arterioscler Thromb Vasc Biol 20:1704-1706.
3. Mansoor MA, Svardal AM, Ueland PM. 1992. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 200:218-229.
4. Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, Budy B, Ketterer ME, Jacobsen DW. 2001. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 276:30111-30117.
5. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. 1999. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 12:439-446.
6. Chao CL, Tsai HH, Lee CM, Hsu SM, Kao JT, Chien KL, Sung FC, Lee YT. 1999. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis 147:379-386.
7. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G. 1997. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277:1775-1781.
8. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. 1997. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236.
9. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, Rosenberg IH, Wilson PW. 2003. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 289:1251-1257.
10. Wald DS, Law M, Morris JK. 2002. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 325:1202.
11. Ubbink JB, Vermaak WJ, van der MA, Becker PJ, Delport R, Potgieter HC. 1994. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 124:1927-1933.
12. Venn BJ, Mann JI, Williams SM, Riddell LJ, Chisholm A, Harper MJ, Aitken W. 2002. Dietary counseling to increase natural folate intake: A randomized, placebo-controlled trial in free-living subjects to assess effects on serum folate and plasma total homocysteine. Am J Clin Nutr 76:758-765.
13. Hackam DG, Peterson JC, Spence JD. 2000. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens 13:105-110.
14. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. 2001. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345:1593-1600.
15. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. 2002. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart study: A randomized controlled trial. JAMA 288:973-979.
16. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. 2004. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291:565-575.
17. Anderson JL, Jensen KR, Carlquist JF, Bair TL, Home BD, Muhlestein JB. 2004. Effect of folic acid fortification of food on homocysteine-related mortality. Am J Med 116:158-164.
18. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial: An efficacy analysis. Stroke 36:2404-2409.
19. Robertson J, Iemolo F, Stabler SP, Allen RH, Spence JD. 2005. Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ 172:1569-1573.
20. Ventura P, Panini R, Abbati G, Marchetti G, Salvioli G. 2003. Urinary and plasma homocysteine and cysteine levels during prolonged oral N-acetylcysteine therapy. Pharmacology 68:105-114.
21. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. 2004. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 109:369-374.
22. House AA, Eliasziw M, Urquhart BL, Freeman DJ, Spence JD. 2004. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodia-lysis patients: A placebo-controlled, double-blind, randomized trial. Am J Kidney Dis 44:689-694.
23. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM, Taylor LM, Jr. 1994. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 40:873-881.
24. Lauterburg BH, Nguyen T, Hartmann B, Junker E, Kupfer A, Cerny T. 1994. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 35:132-136.
25. Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Ferez R. 2000. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res 6:1314-1321.
26. Smith PF, Booker BM, Creaven P, Perez R, Pendyala L. 2003. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. J Clin Pharmacol 43:1324-1328.
27. Stofer-Vogel B, Cerny T, Kupfer A, Junker E, Lauterburg BH. 1993. Depletion of circulating cyst(e)ine by oral and intravenous mesna. Br J Cancer 68:590-593.
28. Kang SS, Wong PW, Glickman PB, MacLeod CM, Jaffe IA. 1986. Protein-bound homocyst(e)ine in patients with rheumatoid arthritis undergoing D-penicillamine treatment. J Clin Pharmacol 26:712-715.
29. Keire DA, Mariappan SV, Peng J, Rabenstein DL. 1993. Nuclear magnetic resonance studies of the binding of captopril and penicillamine by serum albumin. Biochem Pharmacol 46:1059-1069.
30. Aposhian HV, Aposhian MM. 1990. meso-2,3-Dimercaptosuccinic acid: Chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol Toxicol 30:279-306.
31. Lewis SD, Misra DC, Shafer JA. 1980. Determination of interactive thiol ionizations in bovine serum albumin, glutathione, and other thiols by potentiometric difference titration. Biochemistry 19:6129-6137.
32. Narazaki R, Hamada M, Harada K, Otagiri M. 1996. Covalent binding between bucillamine derivatives and human serum albumin. Pharm Res 13:1317-1321.
33. Friedman M, Cavins JF, Wall JS. 1965. Relative nucleophilic reactivities of amino groups and mercaptide ions in addition reactions with alpha, beta-unsaturated compounds. J Am Chem Soc 87:3672-3681.
34. Benesch RE, Benesch R. 1955. The acid stength of the SH group in cysteine and related compounds. J Am Chem Soc 77:5877-5881.
35. Souid AK, Fahey RC, Aktas MK, Sayin OA, Karjoo S, Newton GL, Sadowitz PD, Dubowy RL, Bernstein ML. 2001. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study. Drug Metab Dispos 29:1460-1466.
36. The Merck Index. 1996. Merck Research Laboratories: Whitehouse Station, New Jersey.